Today: 9 June 2026
Intel stock jumps 10% as chip rally widens; CFO share buy back in focus
28 January 2026
1 min read

Intel stock jumps 10% as chip rally widens; CFO share buy back in focus

New York, Jan 28, 2026, 1:19 PM (EST) — Regular session

  • Intel shares jump roughly 10% in early afternoon trading.
  • Chipmakers rose on strong cues from Texas Instruments and ASML.
  • A filing reveals Intel CFO David Zinsner purchased shares in the company on Monday.

Intel Corp shares climbed 10.4%, reaching $48.51 by 1:19 p.m. EST Wednesday. The stock peaked at $49.22 and dipped as low as $45.78 during the session. Trading volume hit roughly 129 million shares.

The surge followed a wider rally in semiconductors as investors searched for signs that AI data center demand—those huge server farms powering AI models—is spreading beyond a handful of big names. Texas Instruments raised its quarterly outlook, while ASML’s bookings, a key gauge of new orders, came in nearly double analyst forecasts. Nvidia, Micron, and AMD all gained ground as well. “Companies across the broader supply chain … are expanding their growth plans,” said Louise Dudley, portfolio manager for global equities at Federated Hermes. Reuters

The broader market lent support. The S&P 500 inched past 7,000 briefly, marking a first, as traders digested the Federal Reserve’s latest rate move alongside a fresh batch of megacap earnings.

Intel caught the market’s eye with insider buying activity. A recent regulatory filing revealed that CFO David Zinsner snapped up 5,882 shares on Jan. 26 at $42.50 apiece, boosting his total direct stake to 247,392 shares.

Intel’s shares plunged 17% last Friday following a disappointing forecast that missed quarterly revenue and profit expectations. The company also flagged difficulties meeting demand for server chips powering AI data centers. “You have to put up the revenue growth to justify the run-up,” said Julian McManus, a portfolio manager at Janus Henderson. Reuters

Intel projected first-quarter revenue between $11.7 billion and $12.7 billion, with adjusted earnings roughly breaking even. On the earnings call, CFO Zinsner noted that supply would hit its lowest point in Q1 but should improve as the year progresses.

That bounce, however, doesn’t resolve the bigger issue Intel faces: can it scale up supply quickly enough without running into new manufacturing or logistics problems? Any further delays in server-chip availability might send the stock sliding again.

Investors are eyeing whether the chip rally signals a wider re-rating or just a short-lived risk-on spike before central-bank announcements and earnings reports. In any case, Intel usually follows the broader semiconductor trend when the sector heats up.

The next key event is set for Wednesday, with the Fed unveiling its policy decision at 2 p.m. EST. About half an hour later, Chair Jerome Powell will address the press.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus
Previous Story

Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom
Next Story

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom

Go toTop